Faculty Bibliography

Background: CSF have lower HRQoL compared to US Standard Population. We have shown previously that HRQoL results need to be controlled for the last stone event and comorbidities. We now show the first longitudinal HRQoL domain profiles for baseline and two yearly follow-ups.
Method(s): CSF were enrolled from the RKSC registry. HRQoL was measured with the generic non-disease specific SF-36v2. Results were calculated as norm-based scores (NBS) based on US Standard Population (Domain score mean = 50). We selected 3 stone frequency groups (SFG): low (stone-free during observation period), medium (minimum of one stone event between 31-365 days) and high (stone event always present within 30 days of the survey), and compared the groups' HRQoL at baseline and second follow-up.
Result(s): We scored 386 surveys. 78 participants (32 males and 46 females) were compared at baseline and 2 follow-up assessments. Mean age was 45 years (male 44/ female 46). Repeated measure ANOVA showed no difference within each SFG over time (Fig 1). However, domain scores were significantly different between SFG's (p<0.05) at each time point, with low>medium>high stone frequency. Whether surgical intervention was required, and type, were not predictors of HRQoL outcomes. Better HRQoL tracked with lower cystine excretion per liter on 24h urine collections; lower cystine capacity and higher citrate doses were underpowered (NS).
Conclusion(s): CSF with high stone event rates experience worse HRQoL over time, while CSF with no stone events achieved better HRQoL than US standard. Clinnical data suggest that the high SFG is undertreated

Neurotrophins play critical roles in the survival, maintenance and death of neurons. In particular, proneurotrophins have been shown to mediate cell death following brain injury induced by status epilepticus (SE) in rats. Previous studies have shown that pilocarpine-induced seizures lead to increased levels of proNGF, which binds to the p75NTR-sortilin receptor complex to elicit apoptosis. A screen to identify compounds that block proNGF binding and uptake into cells expressing p75 and sortilin identified lithium citrate as a potential inhibitor of proNGF and p75NTR-mediated cell death. In this study, we demonstrate that low, submicromolar doses of lithium citrate effectively inhibited proNGF-induced cell death in cultured neurons and protected hippocampal neurons following pilocarpine-induced SE in vivo. We analyzed specific mechanisms by which lithium citrate afforded neuroprotection and determined that lithium citrate prevented the association and internalization of the p75NTR-sortilin receptor complex. Our results demonstrate a novel mechanism by which low-dose treatments of lithium citrate are effective in attenuating p75NTR-mediated cell death in vitro and in vivo.

Background/UNASSIGNED:The corpus callosum is implicated in the pathophysiology of autism spectrum disorder (ASD). However, specific structural deficits and underlying mechanisms are yet to be well defined. Methods/UNASSIGNED:) diffusivities, which reflect myelination and microstructural organization of the extracellular space. The relationships between DKI metrics and processing speed, a cognitive feature known to be impaired in ASD, were also examined. Results/UNASSIGNED: > .05). Conclusion/UNASSIGNED:Decreased DKI metrics suggested that ASD may be associated with axonal deficits such as reduced axonal caliber and density in the corpus callosum, especially in the mid and posterior callosal areas. These data suggest that impaired interhemispheric connectivity may contribute to decreased processing speed in ASD participants.

Optogenetics allows for optical manipulation of neuronal activity and has been increasingly combined with intra- and extra-cellular electrophysiological recordings. Genetically-identified classes of neurons are optically manipulated, though the versatility of optogenetics would be increased if independent control of distinct neural populations could be achieved on a sufficient spatial and temporal resolution. We report a scalable multi-site optoelectrode design that allows simultaneous optogenetic control of two spatially intermingled neuronal populations in vivo. We describe the design, fabrication, and assembly of low-noise, multi-site/multi-color optoelectrodes. Each shank of the four-shank assembly is monolithically integrated with 8 recording sites and a dual-color waveguide mixer with a 7 × 30 μm cross-section, coupled to 405 nm and 635 nm injection laser diodes (ILDs) via gradient-index (GRIN) lenses to meet optical and thermal design requirements. To better understand noise on the recording channels generated during diode-based activation, we developed a lumped-circuit modeling approach for EMI coupling mechanisms and used it to limit artifacts to amplitudes under 100 μV upto an optical output power of 450 μW. We implanted the packaged devices into the CA1 pyramidal layer of awake mice, expressing Channelrhodopsin-2 in pyramidal cells and ChrimsonR in paravalbumin-expressing interneurons, and achieved optical excitation of each cell type using sub-mW illumination. We highlight the potential use of this technology for functional dissection of neural circuits.

Vanishing white matter (VWM) disease is an autosomal genetic leukodystrophy caused by mutations in subunits of eukaryotic translation initiation factor 2B (eIF2B). The clinical symptoms exhibit progressive loss of white matter in both hemispheres of the brain, accompanied by motor functions deterioration, neurological deficits, and early death. To date there is no treatment for VWM disease. The aim of this work was to expedite rational development of a therapeutic opportunity. Our approach was to design a computer-aided strategy for an efficient and reliable screening of drug-like molecules; and to use primary cultures of fibroblasts isolated from the Eif2b5^R132H/R132H VWM mouse model for screening. The abnormal mitochondria content phenotype of the mutant cells was chosen as a read-out for a simple cell-based fluorescent assay to assess the effect of the tested compounds. We obtained a hit rate of 0.04% (20 hits out of 50,000 compounds from the selected library). All primary hits decreased mitochondria content and brought it closer to WT levels. Structural similarities between our primary hits and other compounds with known targets allowed the identification of three putative cellular pathways/targets: 11β-hydroxysteroid dehydrogenase type 1, Sonic hedgehog (Shh), and Sigma-1-Receptor (S1R). In addition to initial experimental indication of Shh pathway impairment in VWM mouse brains, the current study provides evidence that S1R is a relevant target for pharmaceutical intervention for potential treatment of the disease. Specifically, we found lower expression level of S1R protein in fibroblasts, astrocytes, and whole brains isolated from Eif2b5^R132H/R132H compared to WT mice, and confirmed that one of the hits is a direct binder of S1R, acting as agonist. Furthermore, we provide evidence that treatment of mutant mouse fibroblasts and astrocytes with various S1R agonists corrects the functional impairments of their mitochondria and prevents their need to increase their mitochondria content for compensation purposes. Moreover, S1R activation enhances the survival rate of mutant cells under ER stress conditions, bringing it to WT levels. This study marks S1R as a target for drug development toward treatment of VWM disease. Moreover, it further establishes the important connection between white matter well-being and S1R-mediated proper mitochondria/ER function.

Cortical mechanisms that regulate acute or chronic pain remain poorly understood. The prefrontal cortex (PFC) exerts crucial control of sensory and affective behaviors. Recent studies show that activation of the projections from the PFC to the nucleus accumbens (NAc), an important pathway in the brain's reward circuitry, can produce inhibition of both sensory and affective components of pain. However, it is unclear whether this circuit is endogenously engaged in pain regulation. To answer this question, we disrupted this circuit using an optogenetic strategy. We expressed halorhodopsin in pyramidal neurons from the PFC, and then selectively inhibited the axonal projection from these neurons to neurons in the NAc core. Our results reveal that inhibition of the PFC or its projection to the NAc, heightens both sensory and affective symptoms of acute pain in naïve rats. Inhibition of this corticostriatal pathway also increased nociceptive sensitivity and the aversive response in a chronic neuropathic pain model. Finally, corticostriatal inhibition resulted in a similar aversive phenotype as chronic pain. These results strongly suggest that the projection from the PFC to the NAc plays an important role in endogenous pain regulation, and its impairment contributes to the pathology of chronic pain.

Background: Behavioral methods enhance the effectiveness of lifestyle interventions, but are often resource intensive. Although mobile health (mHealth) technology can help create lower input interventions, their feasibility, acceptability and efficacy have not been adequately evaluated in hemodialysis (HD) patients.
Method(s): Maintenance HD patients with persistent hyperphosphatemia (n=40) were randomized to receive: (1) educational (Edu) videos (EDU), (2) Edu + mobile selfmonitoring (SM) with MyNetDiary (MON), or (3) Edu + SM + social cognitive theory (SCT)-based behavioral counseling videos (SCT) over a 12-week period with videos for each group delivered using iPads. Serum phosphorus concentrations (sPO4) were measured at baseline, 12 and 24 weeks, and a 5-point Likert scale survey on the mHealth technology was completed at 24-weeks. Two participants in the EDU group with no follow-up sPO4 measurements were excluded; missing sPO4 measurements at 12-and 24-weeks were imputed by carrying forward the most recent sPO4 values.
Result(s): At the end of the intervention phase (12-weeks), there was a non-significant trend towards greater decreases in sPO4 in the MON (-0.5+/-1.6 mg/dL, p=0.32) and SCT (-0.3+/-2.1 mg/dL, p=0.56) groups compared to the EDU group (+0.2+/-1.4 mg/dL), but these differences had mostly disappeared by the end of the monitoring phase (24-weeks) (EDU +0.1+/-1.2 mg/dL, MON -0.1+/-1.9 mg/dL, SCT -0.1+/-2.1 mg/dL). Most participants agreed or strongly agreed that the iPads were convenient (64%), and SM helped them stay motivated (68%), take binders (61%), and limit phosphorus intake (68%). Relatively few participants reported that they agreed or strongly agreed that they sometimes "got lost" maneuvering the iPad programs (24%), felt that SM wasn't worthwhile (16%), or would have preferred face-to-face meetings offsite (4%).
Conclusion(s): Many HD patients are willing, able and report benefits of engaging in technology-supported behavioral interventions involving SM and SCT. Although these programs are easy to disseminate with limited resources once developed, any benefits for phosphorus management in HD patients may last only as long as the intervention is active

Background: Mucosal immunity may be critical to protection from HIV acquisition. Serum antibodies (Abs) targeted specifically to the region of the V2 loop harboring HIV's a4b7 integrin receptor binding site were associated with protection from HIV acquisition in humans. Mucosal Abs of this type may have been further associated with protection in a matched non-human primate model. Cholera toxin B (CTB) is a powerful mucosal adjuvant. We engineered CTB to display the SIVmac251 region of the V2 loop harboring the a4b7 site for testing in Rhesus macaques.
Method(s): The SIVmac251 a4b7 site was fused to CTB and the integrity of the immunogen was confirmed by X-ray crystallography. Antigenicity of the construct was confirmed with the ITS-12 monoclonal antibody. Serum immunogenicity was tested in rabbits and mucosal immunogenicity in young male Rhesus macaques. The macaque study compares 5 intramuscular (IM) and rectal topical co-administrations of CTB-V2 over 24 weeks to a matched-timeline regimen of two sequential DNA SIV gp120 immunizations followed by three ALVAC-SIV immunizations, the last two of which are coadministered with the IM and mucosal CTB-V2 protein boost.
Result(s): The engineered CTB-V2 protein binds galactose, which approximates mucosal GM1-gangliosides, binds ITS-12 potently and elicits titers >10k against the SIVmac251 a4b7 site in 5 of 5 rabbits. Rhesus macaques were successfully inoculated rectally with 200ug of this protein and tolerated the immunization well. The serum and mucosal responses were profiled.
Conclusion(s): Anti-V2, a4b7-site-targeted antibodies may be elicited by mucosal application of an engineered, validated CTB-V2 immunogen. Comparison to potent ALVAC-based regimens may provide insight into protective immune responses elicited by vaccination